Navigation Links
Fresenius Leads with nearly 50% of the Growing U.S. Dialysis Devices and Concentrates Market, Reports iData Research
Date:11/18/2013

Vancouver, BC (PRWEB) November 18, 2013

iData Research, the leading global authority in medical device market and pharmaceutical market research, has recently published a report for the U.S. dialysis devices and concentrates markets. The report estimates a combined market value of $1,650 million and growing. The total market is comprised of the markets for hemodialysis machines, dialysis catheters, dialysis concentrates, dialyzers, dialyzer reprocessing machines, hemodialysis bloodlines, AV fistula needles, AV grafts, AV declotting devices, guidewires, introducer sheaths and water treatment systems.

There is an ever expanding demographic of Americans suffering from end-stage renal disease (ESRD). Due to this growing patient population amongst other factors detailed in the report, the total dialysis device and concentrates market will grow to a value of almost $2 billion over a ten year forecast period.

Water treatment systems comprise the fastest growing market with trends towards more purchases of expensive heat disinfectant systems. Over the next few years, the sales of heat disinfectant water treatment systems will grow to account for nearly 75% of all water treatment systems. “Chemically disinfected systems have long been the standard for the treatment of water used for dialysis,” says Dr. Kamran Zamanian, CEO iData Research. “However, stricter regulations and enforcement have increased the need for products that can provide the highest level of quality assurance without demanding frequent servicing and labour hours.” These demands are resulting in increased usage of heat based disinfectant water treatment systems. Although such systems are often much more costly to install initially, their operating costs, reduced labour requirements and quality of water treatment will continue to result in strong market growth.

Fresenius is the leading competitor of the total dialysis device and concentrates market with almost half of the total market share. The company achieves their leading position in the market through successfully participating in more dialysis segments than any of its competitors. Fresenius also owns and operates many of its own dialysis centers, which account for a large proportion of all dialysis centers in the United States.

Competitors analyzed in the report include C. R. Bard, MarCor, Medcomp, Baxter, Medisystems, Medivators, Covidien, Asahi Kasei Medical, B. Braun, Rockwell, Teleflex Medical, AngioDynamics, AmeriWater, Terumo, Edwards Lifesciences, NxStage Medical, Gambro, MEDRAD, Cook Medical, W. L. Gore, Cordis, Kawasumi Laboratories, Argon Medical, LeMaitre Vascular, Maky, etc.

The information above is derived from a market intelligence report entitled U.S. Dialysis Devices and Concentrates Market. Click here for a free synopsis.

About iData Research
iData Research is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers market research for infusion therapy, anesthesia, diabetes and more.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11337269.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuit News: Bernstein Liebhard LLP Comments on Fresenius FDA Warning Letter, as GranuFlo Recall Claims Mount
2. New Fresenius NaturaLyte, GranuFlo Dialysis Heart Attack Lawsuit Allegations Update: Resource4thePeople Reports Important Hearing Is Scheduled in Fresenius Multidistrict Litigation
3. Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama
4. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
5. Inside Job: Medical Negligence Lawyers at Console & Hollawell Comment on Risks to Dialysis Patients and Impending Legal Action Over Fresenius Controversy
6. d’Oliveira & Associates Releases Webpage With Current Information on Fresenius Lawsuits
7. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
8. Rapid testing to diagnose influenza leads to more appropriate care in the ED
9. Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both
10. CWRU psychologist leads $1.4 million project to study spiritual struggles and stress links
11. Constant Confusion with Obama Care Leads Southern Californians to Trusted and Local Burbank Insurance Exchange Help
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: